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Immunotherapy, the next step in the treatment of myeloma 
The improved understanding of the molecular pathways involved in cancer development 
has allowed for the rational design of drugs that target and selectively interfere with 
oncogenic signaling pathways, thus moving from the “one size fits all” approach to a more 
personalized therapy. As a consequence, cancers, including multiple myeloma, are now 
treated effectively, with prolonged survival.1 Nevertheless, nearly all myeloma patients will 
experience acquired resistance arising from a number of alterations, such as gene 
mutation, amplification or alternative splicing, and different mechanisms may be in 
operation in different cells due to intra-tumor heterogeneity.  In addition, the tumor and its 
microenvironment may lead to immunosuppression in the bone marrow,2 causing a loss of 
tumor immunosurveillance and providing protection to targeted cell death.3 In this scenario, 
recent findings suggest the central role of immunotherapeutic agents, including 
monoclonal antibodies, with a dual mechanism of action, as they can act directly against 
cancer cells and regulate cellular immune response.4  
This is indeed the model of action of elotuzumab. Elotuzumab is a humanized monoclonal 
antibody targeted against Signalling Lymphocytic Activation Molecule Family member 7 
(SLAMF7). It has a novel dual mechanism of action, as it binds to SLAMF7 on myeloma 
cells, while also binding to CD16 on natural killer (NK) cells, activating NK cells to lyse the 
antibody-bound tumor cells, thus with selective killing of myeloma cells and minimal effects 
on normal tissue. In addition, elotuzumab directly activates NK cells by binding to SLAMF7 
on their surface and improves their antimyeloma activity through the interaction with 
signaling intermediary EAT-2.5 Based on this knowledge, elotuzumab is under evaluation 
in clinical trials and it showed to be safe and effective as single agents, as well as in 
combination with other agents such as bortezomib and lenalidomide.4 
In the Lancet Haematology, the authors present final results from a phase 1b/2 
randomized study of elotuzumab – 10 mg/kg or 20 mg/kg - in combination with 
lenalidomide and dexamethasone in relapsed myeloma patients who received one to three 
prior lines of therapy.6 Twenty-nine patients were enrolled in the phase 1 and 73 in the 
phase 2. In the latter, 36 patients were randomized to receive elotuzumab at 10 mg/kg and 
37 patients to elotuzumab at 20 mg/kg. The overall response rate was 84%, including a 
very good partial response rate of 42%, and the median progression-free survival was 28·6 
months. No significant differences in outcome were detected between elotuzumab at 10 or 
20 mg/kg. Although cross trial comparisons should be considered with caution, the efficacy 
of this combination was also confirmed in the phase 3 ELOQUENT-2 trial,7 where patients 
receiving elotuzumab plus lenalidomide-dexamethasone had a relative reduction of 30% in 
the risk of disease progression or death compared with the control group. Of note, in the 
subgroup of patients receiving elotuzumab and who achieved a very good partial response 
or better the median progression-free survival was not reached. Thus, elotuzumab plus 
lenalidomide-dexamethasone showed to be particularly effective with reduced tumor mass.  
The phase 1b-2 study showed that the elotuzumab combination was well tolerated, and 
the most common, all grade adverse events were diarrhea (66%), muscle spasms (62%) 
and fatigue (56%). The good safety profile was confirmed in the phase 3 ELOQUENT-2 
study,7 which found no significant difference between elotuzumab-lenalidomide-
dexamethasone and the control group in terms of rates of grade 3-4 toxicities: neutropenia 
was 34% versus 44%, thrombocytopenia 19% versus 20%, and anemia 19% versus 21%, 
in the elotuzumab and in the control groups, respectively. Elotuzumab induced an increase 
in lymphocytopenia (77% versus 49%), which may reflect alterations in lymphocyte 
trafficking, including NK cells, with no evidence of autoimmunity or other sequelae of 
immune dysregulation.  
The results of the phase 1b-2 study, and in particular those of the ELOQUENT-2 study, 
suggest that the combination of elotuzumab plus lenalidomide-dexamethasone can be 
considered one of the new standards of care for relapsed/refractory myeloma patients, 
with no additional toxicity. Longer follow-up is needed to assess whether a subgroup of 
patients may have a very prolonged remission duration. Further evidence is needed to 
support the role of treatment strategies that combine cytoreduction and tumor 
immunosurveillance in multiple myeloma, as already demonstrated in other tumors.  
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